Skip to content
glp1.howSign in

Access

Endotoxin

A toxin from the outer wall of certain bacteria that can contaminate poorly made injectable products and trigger fever, chills, and serious reactions.

By the glp1.how editorial teamReviewed

An endotoxin is a toxic component of the outer cell wall of certain bacteria, released when the bacteria break down. When it contaminates an injectable product, it can cause fever, chills, low blood pressure, and other serious reactions, even if the product no longer contains live bacteria.

Controlling endotoxin levels is a routine part of regulated sterile drug manufacturing. It is a documented risk with unregulated or grey-market peptides and injectables made without that oversight: when researchers test-bought semaglutide from illegal online pharmacies, endotoxin turned up in all three vials that arrived (Ashraf et al., Journal of Medical Internet Research, 2024 (external link)). That is one reason the source and quality controls of an injected product matter. See research peptides and GLP-1 medications.

safetyinjectablescontamination

Revision history

Updated 1 time since Jul 18, 2026 · show changes
  1. v2

    Body revised

  2. v1

    Change tracking began

Related guides

  • How compounded GLP-1 medications are made — and how that differs from the branded pens · A compounded GLP-1 is mixed from raw active ingredient at a pharmacy; it does not come off a branded production line. This guide explains how the drug substance is sourced, how the formula and dose are set, how a sterile compounding pharmacy makes the vial, and how that compares with the tightly controlled, FDA-approved process behind Ozempic, Wegovy, and Zepbound.
  • How to verify a pharmacy is legitimate: BeSafeRx, NABP, and your state board · Our sourcing guides keep ending on the same instruction (verify the pharmacy with your state board, the NABP, or FDA's BeSafeRx) without saying how. This is the step-by-step: the free tools each one offers, what red flags to look for, how to pull a pharmacy's license record, and how to check your own pen's lot number against FDA's counterfeit alerts. About five minutes, start to finish.
  • Pharmacy sources for GLP-1 medications: compounded, telehealth, and counterfeit risks · The brand shortages that made compounded GLP-1s widely available ended in late 2024 and early 2025, and where people get these drugs has shifted since. Counterfeit Ozempic has turned up in the legitimate supply chain three times. This guide shows how to tell the fully legitimate routes from compounded grey areas and outright dangerous sellers, and how to vet any source before you inject.
  • "Research peptides" and GLP-1 medications: what they are, and what the label doesn't tell you · "Research peptides" are GLP-1 drugs such as semaglutide, tirzepatide, and retatrutide, sold as powder in vials stamped "research use only, not for human consumption." That label is a legal workaround and says nothing about safety. This guide covers where these products come from, what independent testing found inside the vials, why the "research" disclaimer does not make them regulated or safe, and the documented harms behind a rise in poison-control calls.
  • Applying for a GLP-1 patient assistance program: step by step · Novo Nordisk's PAP and Lilly Cares can provide Ozempic or Trulicity free to people who qualify by income and insurance status, but as of September 2026 neither covers Wegovy, Zepbound, Saxenda, or Foundayo. Here's who qualifies, the 2026 income limits in dollars, the documents you need, your prescriber's role, turnaround and renewal, what to do if you're denied, and how PAPs differ from savings cards and direct-pay.
  • Manufacturer savings cards for every branded GLP-1, including the new pills: a side-by-side guide · Novo Nordisk and Eli Lilly run copay savings cards for their branded GLP-1s, pills and injections alike, but prices, caps, and rules differ by drug, and two cards are closed to new enrollees. This guide lists every current card for Wegovy, Ozempic (pen and the new Ozempic tablets, which replaced Rybelsus in the US in May 2026), Zepbound, Mounjaro, Trulicity, and Foundayo side by side as of September 2026, plus what happened to Saxenda and Victoza.

Related terms

  • Semaglutide · A GLP-1 receptor agonist medication made by Novo Nordisk, sold under the brand names Ozempic (type 2 diabetes) and Wegovy (weight management), each as an injection or a pill.

Was this helpful?

Improve this page